TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06978725: A Study of Brepocitinib in Adults With Cutaneous Sarcoidosis

Sponsor: Priovant Therapeutics, Inc. · Phase: PHASE2/PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 168 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,118,808

Rescue Site Savings

+$2,065,704

Unlock Full NCT06978725 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06978725 Rescue Dossier →